Envío mundial con seguimiento | Aprox. 9–14 días hábiles

Tu carrito

Tu carrito está vacío

Comenzar a explorar

Envío gratuito en pedidos superiores a €500.

Subtotal€0
Proceder al pago
CognitivoClínico temprano

DSIP

Investigación publicada y base de evidencia

Delta sleep-inducing peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 from cerebral venous blood of sleep-induced rabbits. Despite five decades of study, no DSIP gene, precursor protein or receptor has been identified, and the peptide's status as an endogenous sleep factor remains contested. Human work is concentrated in the 1980s and early 1990s and includes small double-blind studies in insomnia, chronic pain and opioid withdrawal with inconsistent results; recent research is almost entirely rodent work on stroke, stress and drug-delivery constructs.

En resumen
  • El DSIP es un péptido de nueve aminoácidos aislado de sangre cerebral de conejo en 1977.
  • Estudios humanos pequeños en los años 1980 y 1990 reportaron resultados inconsistentes.
  • No se ha identificado ningún receptor o gen del DSIP y su papel natural es disputado.

36 estudios · 1 desde 2023 · más reciente 2024

Estudios citados
36
Publicados en 2023+
1
Artículo más reciente
2024
Última revisión
oct 2026

Temas recurrentes en la literatura

  • slow-wave sleep
  • endogenous sleep factor hypothesis
  • blood-brain barrier transport
  • stress and HPA axis
  • opioid withdrawal
  • antioxidant and geroprotective effects
  • unidentified receptor

Identificadores del compuesto

CAS
62568-57-4
PubChem
68816

Estado regulatorio

No recomendado por un comité asesor de la FDA.

El 23–24 July 2026 el Comité Asesor de Formulación Farmacéutica de la FDA consideró DSIP, escuchado bajo el nombre emideltide, para la Lista 503A de Sustancias a Granel y declinó recomendar su inclusión en un voto reportado de 6–7 with one abstention. The only one of the seven peptides the committee declined to recommend. It was heard under the name emideltide.

Esto no es una aprobación. El comité asesora; no decide. La recomendación no es vinculante, la FDA no ha completado el proceso de reglamentación que cambiaría formalmente algo, y la inclusión en la Lista 503A de Sustancias a Granel no equivale a la aprobación de un medicamento por la FDA. La lista también rige la formulación farmacéutica para pacientes, que es una actividad separada del suministro para uso exclusivo en investigación.

Lo que realmente hizo el voto asesor de julio de 2026 expone el proceso, los otros compuestos considerados y las cuatro cosas que el voto se reporta erróneamente como significando.

Identidad química

Qué es DSIP, químicamente.

Fórmula molecular
C35H48N10O15
Peso molecular
848.8 g/mol
Número CAS
62568-57-4
PubChem CID
68816
También escrito como

Emideltide

Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.

La evidencia

36 estudios publicados.

Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.

  1. 01Clínico humano2009

    Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia

    Pomfrett CJ, et al. · European Journal of Anaesthesiology · randomised controlled trial, 24 female ASA I-II patients; intravenous DSIP 25, 50 or 100 nmol/kg vs saline during isoflurane anaesthesia

    DSIP increased heart rate, decreased heart rate variability and, contrary to the hypothesis, reduced delta rhythm and increased bispectral index at 25 nmol/kg. The authors concluded DSIP lightened rather than deepened anaesthetic depth.

  2. 02Clínico humano2004· Russian (English abstract)

    [Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide].

    Odin VI, et al. · Adv Gerontol · uncontrolled pilot study, n=11 elderly patients with diabetes (mean age 66.3); course of the DSIP-containing drug Deltaran, assessed before and 60 days after starting

    After treatment, SCAG-scale scores improved for recent memory (p=0.003), depressed mood (p=0.019), emotional lability (p=0.002) and anxiety, sleep quality improved, post-load glycaemia fell (p=0.033) and basal and stimulated growth hormone fell. There was no control group.

  3. 03Clínico humano2001

    Intranasal administration of delta sleep-inducing peptide increases P300.

    Hruz P, et al. · J Clin Psychopharmacol · research letter on intranasal DSIP and the P300 event-related potential; design and sample size not available in the registry record

    The title reports that intranasal administration of DSIP increased P300. Results are not available in the abstract (PubMed holds no abstract).

  4. 04Clínico humano1998

    Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial

    Backmund M, Meyer K, Rothenhaeusler HB, Soyka M · Journal of Clinical Psychopharmacology · open clinical trial in opioid detoxification

    This open-label report described use of DSIP during opioid detoxification. It was published as a short communication without a control group.

  5. 05Clínico humano1995

    Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy

    Vgontzas AN, Friedman TC, Chrousos GP, Bixler EO, Vela-Bueno A, Kales A · Peptides · cross-sectional plasma sampling: 9 sleep apnoea patients, 10 narcolepsy patients, 11 normal controls, plus a second cohort

    Morning plasma DSIP-like immunoreactivity did not differ significantly between sleep apnoea patients, narcolepsy patients and controls. The findings did not support single plasma DSIP measures as a disease marker.

  6. 06Clínico humano1995

    Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion.

    Späth-Schwalbe E, et al. · Psychoneuroendocrinology · placebo-controlled intravenous infusion studies in healthy young men: CRH-stimulation experiment (n=5 in each condition) and meal-related secretion experiment (n=10)

    ACTH and cortisol responses to human CRH were almost identical during DSIP and placebo infusion, and the meal-related midday ACTH and cortisol surge was also unaffected. The authors concluded the data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man.

  7. 07Clínico humano1994

    Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep

    Friedman TC, et al. · The Journal of Clinical Endocrinology and Metabolism · human diurnal sampling with concurrent polysomnography and body temperature

    Plasma DSIP correlated positively with body temperature and negatively with REM and slow-wave sleep, a pattern opposite to that expected of a circulating slow-wave-sleep-promoting factor.

  8. 08Clínico humano1994

    Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men.

    Chiodera P, et al. · Horm Res · placebo-controlled infusion study (PubMed type: randomised controlled trial), 8 healthy men aged 23-34 plus 7 further subjects; intravenous DSIP vs saline before osmotic and orthostatic stimuli

    DSIP did not change circulating arginine-vasopressin at baseline or its rise after hypertonic saline or standing, but it produced a significant decrease in ACTH compared with the slight physiological decline during saline.

  9. 09Clínico humano1993

    Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women.

    Giusti M, et al. · Psychoneuroendocrinology · controlled study, n=8 healthy women aged 17-36; intravenous DSIP, arginine and both combined (five women) and DSIP vs placebo infusion for circadian profiles (three women)

    DSIP did not change basal growth hormone or prolactin, their circadian rhythm, or their responses to arginine.

  10. 10Clínico humano1992

    Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study

    Bes F, Hofman W, Schuur J, Van Boxtel C · Neuropsychobiology · double-blind matched-pairs parallel-group trial, n=16 chronic insomnia patients; intravenous DSIP 25 nmol/kg vs glucose placebo on three nights, polysomnography

    Polysomnography showed higher sleep efficiency and shorter sleep latency with DSIP, but the effects were weak and partly attributable to change in the placebo group. The authors concluded short-term DSIP treatment of chronic insomnia was unlikely to be of major therapeutic benefit.

  11. 11Clínico humano1989

    Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man.

    Bjartell A, et al. · Psychoneuroendocrinology · randomized double-blind crossover, n=11 healthy men, single intravenous dose

    Plasma ACTH-like immunoreactivity fell for at least 3 hours after DSIP compared with saline, while plasma cortisol, urinary cortisol and urinary monoamine metabolites were unchanged.

  12. 12Clínico humano1987

    Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

    Schneider-Helmert D · Eur Neurol · placebo-controlled double-blind trial, n=14 middle-aged chronic insomniacs, 7 nights, polysomnography

    Night sleep improved after the first and repeated administrations and the effect persisted into the first placebo night after treatment; sleep efficiency reached the level of normal controls, and daytime alertness and performance increased significantly.

  13. 13Clínico humano1987

    Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

    Monti JM, et al. · Int J Clin Pharmacol Res · double-blind placebo-controlled crossover, chronic insomniacs, 4 nights, polysomnography

    Total sleep time, NREM sleep and stage 2 increased, but differences from placebo were already present at baseline, slow-wave and REM sleep were unchanged, and the authors concluded that the sleep improvement was of little clinical significance.

  14. 14Clínico humano1986

    Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs.

    Schneider-Helmert D · Eur Neurol · uncontrolled sleep-laboratory study, n=18 chronic psychophysiological insomniacs split into middle-aged (29-59) and older (60-83) groups; one week of intravenous DSIP and one week of follow-up

    Sleep in middle-aged insomniacs improved to normal values by the end of treatment and stayed normal during follow-up; in older insomniacs, whose baseline disturbance was about twice as severe, full normalisation came only by the end of follow-up. Effects correlated with the degree of sleep disturbance; there was no placebo group.

  15. 15Clínico humano1984

    Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study

    Larbig W, Gerber WD, Kluck M, Schoenenberger GA · European Neurology · open pilot study, n=7 patients with migraine, vasomotor headache, chronic tinnitus or psychogenic pain; intravenous DSIP over 5 consecutive days then every 48-72 h

    Pain levels fell significantly in 6 of 7 patients relative to baseline, with a concurrent reduction in depressive symptoms. The design was uncontrolled and the sample very small.

  16. 16Clínico humano1984

    DSIP in the treatment of withdrawal syndromes from alcohol and opiates.

    Dick P, et al. · Eur Neurol · open clinical series, n=107 inpatients with alcohol (n=47) or opiate (n=60) withdrawal; intravenous DSIP, no control group

    Clinical withdrawal symptoms and signs disappeared or improved markedly and rapidly in 97% of evaluable opiate and 87% of evaluable alcohol patients, while anxiety decreased more slowly. Opiate patients needed more injections, and tolerance was good apart from headaches in a few patients.

  17. 17Clínico humano1984

    A clinical trial with DSIP.

    Kaeser HE · Eur Neurol · open study, n=7 patients with severe insomnia; a series of DSIP injections, follow-up 3-7 months

    Sleep normalised in all but 1 patient for follow-up periods of 3-7 months, and daytime mood and performance also improved. The author noted a long-standing habit of drug addiction as a possible problem.

  18. 18Clínico humano1983

    Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep

    Schneider-Helmert D, Schoenenberger GA · Neuropsychobiology · five double-blind human studies with single and repeated intravenous DSIP injections, polygraphic recordings and psychophysiological tests

    The authors reported a sleep-induction latency of about 1 h with effects lasting up to 20 h, normalisation of disturbed sleep in insomniacs after four consecutive injections, and increased alertness and performance during waking. Tolerability was good provided injection was slow.

  19. 19Clínico humano1981

    Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.

    Schneider-Helmert D, et al. · Int J Clin Pharmacol Ther Toxicol · double-blind placebo-controlled crossover study, n=6 healthy volunteers (four men, two women); single morning intravenous infusion

    Volunteers reported sleep pressure soon after infusion and total sleep time rose by 59% within a 130-minute interval compared with placebo; the following night showed shorter sleep onset, less stage 1 and better sleep efficiency. Behavioural and EEG analyses found no classic sedation, and no psychological, physiological or biochemical side effects were observed.

  20. 20Clínico humano1981

    The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.

    Schneider-Helmert D, Schoenenberger GA · Experientia · clinical study, n=6 middle-aged chronic insomniacs; acute intravenous DSIP with night polygraphy

    DSIP was followed by longer sleep with fewer interruptions and slightly more REM sleep, without daytime sedation or other side effects; sleep-promoting effects appeared only in the second hour after injection, after a slight arousing effect in the first hour.

  21. 21Animal in vivo2024

    Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models

    Mu X, Qu L, et al. · Frontiers in Pharmacology · PCPA-induced insomnia mouse model, recombinant DSIP fusion peptide expressed in Pichia pastoris

    A recombinantly produced DSIP fusion peptide crossed the blood-brain barrier and produced measurable effects in a chemically induced insomnia mouse model. This is the most recent primary DSIP study indexed in PubMed.

  22. 22Animal in vivo2021

    Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke

    Tukhovskaya EA, et al. · Molecules · Sprague-Dawley rats, focal stroke model

    DSIP administration was associated with recovery of motor function after focal stroke in rats.

  23. 23Animal in vivo2021

    DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion

    Tukhovskaya EA, et al. · Biomedicines · C57Bl/6 mice (cerebral ischaemia) and Sprague-Dawley rats (myocardial ischaemia-reperfusion)

    The DSIP-like KND peptide reduced infarct size in both brain and myocardial ischaemia-reperfusion models when given during reperfusion.

  24. 24Animal in vivo2018

    Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude

    Roy K, et al. · Life Sciences · rodent model of hypobaric hypoxia / simulated high altitude

    Phosphorylated DSIP improved sleep architecture and was associated with restored spatial memory performance and p-CREB expression under simulated high-altitude conditions.

  25. 25Animal in vivo2016

    Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress

    Bobyntsev II, et al. · Bulletin of Experimental Biology and Medicine · rat restraint-stress model, hepatocyte morphology and function

    DSIP modified stress-induced changes in hepatocyte functional state, consistent with a general anti-stress rather than sleep-specific action.

  26. 26Animal in vivo2014

    Effect of delta sleep-inducing peptide on the expression of antioxidant enzyme genes in the brain and blood of rats during physiological aging

    Kutilin DS, Bondarenko TI, et al. · Bulletin of Experimental Biology and Medicine · ageing rats, brain and blood antioxidant enzyme gene expression

    DSIP altered expression of antioxidant enzyme genes in brain and blood of ageing rats, forming part of the Russian geroprotection literature on this peptide.

  27. 27Animal in vivo2012

    Effect of delta sleep-inducing peptide on oxidative modification of proteins in rat tissues and blood during physiological aging

    Bondarenko TI, et al. · Bulletin of Experimental Biology and Medicine · ageing rats, protein carbonylation markers in tissues and blood

    DSIP reduced markers of oxidative protein modification in ageing rats.

  28. 28Animal in vivo2003

    Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.

    Popovich IG, et al. · Mech Ageing Dev · female SHR mice, n=54 per group, lifelong monthly courses of a DSIP preparation (Deltaran) vs saline

    Treatment did not change mean life span or food intake but lowered body weight, increased the life span of the longest-lived 10% and maximum life span, reduced chromosome aberrations in bone marrow, slowed age-related loss of estrous function and lowered total spontaneous tumour incidence 2.6-fold.

  29. 29Animal in vivo1988

    Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat

    Iyer KS, McCann SM · Proceedings of the National Academy of Sciences of the United States of America · rat, immunoneutralisation and administration studies of slow-wave sleep and growth hormone release

    This landmark study reported evidence linking DSIP to slow-wave sleep and sleep-associated growth hormone release in the rat, and is the most frequently cited mechanistic basis for DSIP's sleep claims.

  30. 30Animal in vivo1977

    Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.

    Schoenenberger GA, Monnier M · Proc Natl Acad Sci U S A · rabbits, n=58 incl. controls, double-blind intraventricular infusion of synthetic DSIP, fragments and analogues

    The nonapeptide was isolated from rabbits, sequenced (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and synthesised; of nine synthetic peptides tested, only synthetic DSIP produced significant, specific enhancement of delta and spindle EEG patterns.

  31. 31Revisión2006

    Delta sleep-inducing peptide (DSIP): a still unresolved riddle

    Kovalzon VM, Strekalova TV · Journal of Neurochemistry · critical mini-review

    The authors concluded that the hypothesis of DSIP as a sleep factor is poorly documented and weak, noting that no DSIP gene, protein precursor or receptor had been isolated and that certain synthetic analogues, but not DSIP itself, promoted slow-wave sleep in rabbits and rats.

  32. 32Revisión1984

    Delta-sleep-inducing peptide (DSIP): a review

    Graf MV, Kastin AJ · Neuroscience and Biobehavioral Reviews · foundational narrative review

    This early review consolidated the distribution, pharmacokinetics and reported behavioural actions of DSIP, and established the framing of the peptide as multifunctional rather than sleep-specific.

  33. 33Reporte de caso1997

    Delta sleep-inducing peptide in opioid detoxification.

    Soyka M, Rothenhaeusler HB · Am J Psychiatry · case report (letter) on DSIP during opioid detoxification; details not available in the registry record

    The title and publication type indicate a case report of DSIP use in opioid detoxification. Results are not available in the abstract (PubMed holds no abstract).

  34. 34Reporte de caso1987· German (English abstract)

    [The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia].

    Schneider-Helmert D, et al. · Dtsch Med Wochenschr · case report, 47-year-old woman with chronic delayed sleep phase insomnia and low-dose benzodiazepine dependence; one week of inpatient DSIP under polygraphic control

    The main sleep phase advanced by 5 hours, flunitrazepam was withdrawn abruptly and completely and a normal sleep profile returned; actigraphy during the following week showed the improvement was maintained.

  35. 35Reporte de caso1984

    Effects of DSIP on narcolepsy.

    Schneider-Helmert D · Eur Neurol · case report, 35-year-old man with narcolepsy; repeated DSIP injections, polysomnography and multiple sleep latency testing

    DSIP reduced the frequency of sleep attacks and increased daytime activity, alertness and performance; the night sleep period was compressed, with enhanced REM sleep.

  36. 36Reporte de caso1984

    Sleep disturbances in a case of brain-stem lesions; pharmacological study.

    Laffont F, et al. · Electroencephalogr Clin Neurophysiol · case report, severe insomnia after brain-stem lesions; slow DSIP injection compared with 5-HTP, L-DOPA and clonazepam under repeated polygraphy

    Slow injection of DSIP improved sleep quantitatively and qualitatively, although paradoxical-sleep latency stayed short; the effects were reversible.

Limitaciones

Lo que esta evidencia no establece.

No DSIP receptor, gene or precursor has ever been identified, and the peptide's classification as an endogenous sleep factor is disputed in the primary literature. Human trials are small, mostly pre-1995, used intravenous rather than subcutaneous dosing, and produced inconsistent sleep outcomes; there are no modern randomised controlled trials, no pharmacokinetic characterisation for non-intravenous routes, and no controlled safety data.

Preguntas comunes sobre la investigación.

What is DSIP?

DSIP is a nonapeptide originally isolated from rabbit cerebral venous blood during electrically induced slow-wave sleep. It has been studied since the late 1970s and remains one of the more mechanistically unresolved peptides in the neuroscience literature.

Does the literature explain how DSIP works?

Not conclusively. No receptor has been confirmed and no transduction pathway agreed. Reviewers describe interactions with the hypothalamic-pituitary-adrenal axis and the opioid system, plus reports on thermoregulation and gene expression, but explicitly characterise the overall picture as unresolved.

Why does recent DSIP research have so little to do with sleep?

Because the sleep findings proved difficult to replicate. Work published since 2010 has largely moved to other endpoints — motor recovery after experimental stroke, antioxidant enzyme expression in ageing animals, and stress-model physiology — which is where the current literature sits.

Disponible en nuestro catálogo

Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.